Blog January 18, 2023
What the lecanemab Approval Means for the Life Science Industry
The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.
Blog January 18, 2023
The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.
Blog January 10, 2023
Syneos DEI Advisory Council members share strategies for promoting inclusive workforce behaviors that will position business leaders to sustain their organizations through emerging industry challenges, trends, and regulations.
Blog January 10, 2023
This POV uses Mindset Engine data to explore how tenure connects to burnout for HCPs, and how pharma communicators can use these insights to be more compassionate marketers.
Blog January 6, 2023
In 2022, the FDA took a large step toward helping nearly 30 million Americans with mild-to-moderate hearing loss engage in healthy aging by allowing easier access to hearing aids. Read how this decision relates to the science behind motivation from Kathleen Starr, Ph.D.
Blog January 6, 2023
Tap into insights from the Mindset Engine, a proprietary intelligence platform powered by Syneos Health, to understand how time (or lack thereof) interferes with HPC's abilities to provide breast cancer care, and how healthcare communicators can help.
Blog January 6, 2023
As anticipated, the drug pricing watchdog group, the Institute for Clinical and Economic Review (ICER), published its fourth annual Unsupported Price Increase (UPI) Report on prescription drugs in the United States.
Blog January 5, 2023
In November 2022, Sen. Mike Lee (R-UT) introduced the Biosimilar Elimination Red Tape Act that would prohibit the FDA from requiring that biosimilars undergo switching studies.
Blog December 9, 2022
The World Orphan Drug Congress Europe (WODC) looked back on the remarkable achievements of the last 20 years of the General Pharmaceutical Legislation (GPL) in Europe.
Blog November 22, 2022
At the 2022 BIO International Convention in San Diego, a panel explored how gaps in VC funding of Black- and women-led start-ups impact the development of scientific breakthroughs, new inventions, and business creation.
Blog November 3, 2022
Brand centricity, a very much one-sided approach, is no longer relevant in our industry. Today, we emphasize the importance of a mutual relationship between a brand and its audience. We call this the WE principle.
Blog October 6, 2022
Yesterday, there was widespread celebration across stakeholders following the FDA approval of Amylyx's treatment for ALS, Relyvrio. Now, cheers are turning to criticism, after the price of the drug was announced by the company this morning on their investor call.
Blog August 9, 2022
Applying a behavioral science perspective to consider new ways to engage HCPs and patients.
Blog August 8, 2022
In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.
Blog August 1, 2022
Read on to find out what our behavioral science experts think of Apple’s latest report, and the opportunity to amplify the role of HCPs.
Blog July 20, 2022
Drug pricing legislation continues to forge ahead with a significant healthcare proposal back in play.
Blog July 20, 2022
On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).
Blog July 7, 2022
Patients with learning disabilities, low literacy levels, poor health literacy, and nonnative language skills are often excluded from the routine health monitoring that patient reported outcomes (PROs) can provide. Learn why, and what we can do to shift this trajectory.
Blog July 7, 2022
While significant strides have been made to improve PRO inclusion in clinical trials and routine clinical practice, strategies to include underserved groups are in short supply.
Blog July 7, 2022
Real world evidence: what it is, what it is important, and what it means for healthcare communicators.
Blog June 23, 2022
Suzanne Goss, Executive Vice President of Brand Strategy at Syneos Health Communications, shares her takeaways from the 2022 ASCO convention, and sheds light on the questions we need to ask ourselves as we move toward more equitable care.
Blog June 23, 2022
It’s estimated that 37% of the world’s population are digitally excluded. Learn more about the digital divide, how it relates to patient-reported outcomes, and how we're addressing these issues at Syneos Health Communications.
Blog June 15, 2022
Hear from a few members from our Syneos Health DEI Advisory Council on how DE&I can play a role in the mental health and wellbeing of your employees.
Blog June 15, 2022
CMS has recently finalized a rule that aims to save beneficiaries and pharmaceutical manufactures money. The rule will require that pharmacy concessions be passed through to Medicare beneficiaries at the point of sale and will go into effect in 2024.
Blog June 14, 2022
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
Blog June 2, 2022
The European Federation of Pharmaceutical Industries and Association (EFPIA) Waiting to Access Innovative Therapies (W.A.I.T.) Indicator Survey has been released. The survey examines access to 160 innovative medicines over a 5-year period (2017-2021).
Blog May 25, 2022
As psychedelics gain more attention as treatments for certain mental health disorders, here are a few notes on what the pharmaceutical industry can expect.
Blog May 25, 2022
Syneos Health Communications' in-house wellness expert Leslie Archer tells us how corporate wellness initiatives are integral to a healthy employee, and a healthy company overall.
Blog May 23, 2022
There’s no hard-and-fast formula for how to react (or not react) on social media when a crisis or issue arises. This article shares a few considerations to help guide your decision-making process.
Blog May 12, 2022
While pharmaceutical manufacturers need to continue engaging with the broader healthcare system to help address healthcare disparities in the long term, there is action they can take now.
Blog May 10, 2022
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” Read on to learn what it means for science manufacturers.
Already have a RSS feed reader?
